Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, Shields AL. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adher. 2016;10:1609.

Article  Google Scholar 

Leveque D. Subcutaneous administration of anticancer agents. Anticancer Res. 2014;34(4):1579–86.

CAS  PubMed  Google Scholar 

Roche’s Tecentriq SC receives EC approval for cancer treatment: Pharmaceutical Technology; 2024. Available from: https://www.pharmaceutical-technology.com/news/roche-tecentriq-sc-ec-approval/?cf-view.

Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous trastuzumab (Herceptin®): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res. 2013;2(04):133–40.

Article  Google Scholar 

Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–82.

Article  PubMed  Google Scholar 

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung K, Azim H, et al. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study’s primary analysis of 2573 patients. Eur J Cancer. 2017;82:237–46.

Article  CAS  PubMed  Google Scholar 

Mateos M-V, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol. 2012;3(2):117–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019;15(28):3267–81.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3): e1003583.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (2023): Cochrane; 2023; Available from: www.training.cochrane.org/handbook.

Ciruelos EM, Montano A, Rodriguez CA, Gonzalez-Flores E, Lluch A, Garrigos L, et al. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: results from the ChangHER study (GEICAM/2012-07). Eur J Cancer Care (Engl). 2020;29(4): e13253.

Article  PubMed  Google Scholar 

Denys H, Martinez-Mena CL, Martens MT, D’Hondt RG, Graas ML, Evron E, et al. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Res Treat. 2020;181(1):97–105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valachis A, Sundqvist M, Carlsson L, Li B, Chiesa F, Uhde M, Sanglier T. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden. Future Oncol. 2019;15(23):2733–41.

Article  CAS  PubMed  Google Scholar 

O’Brien GL, O’Mahony C, Cooke K, Kinneally A, Sinnott SJ, Walshe V, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer. 2019;19(3):e440–51.

Article  CAS  PubMed  Google Scholar 

Hedayati E, Fracheboud L, Srikant V, Greber D, Wallberg S, Linder SC. Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska University Hospital in Sweden. PLoS ONE. 2019;14(2): e0211783.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olsen J, Jensen KF, Olesen DS, Knoop A. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. J Comp Eff Res. 2018;7(5):411–9.

Article  PubMed  Google Scholar 

Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, et al. Patients’ preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study. Eur J Cancer. 2017;82:230–6.

Article  CAS  PubMed  Google Scholar 

Cebas AL, Cascajares SC, Bravo SP, Goñi MD, Monterrubio GG, Cardenas MP, Piquero JF. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use. J BUON. 2017;22(2):334–9.

Google Scholar 

Olofsson S, Norrlid H, Karlsson E, Wilking U, Ragnarson TG. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer—an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140–6.

Article  PubMed  Google Scholar 

Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–70.

Article  CAS  PubMed  Google Scholar 

Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26(2):320–5.

Article  CAS  PubMed  Google Scholar 

Tjalma WAA, Van den Mooter T, Mertens T, Bastiaens V, Huizing MT, Papadimitriou K. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol. 2018;221:46–51.

Article  CAS  PubMed  Google Scholar 

Farolfi A, Silimbani P, Gallegati D, Petracci E, Schirone A, Altini M, Masini C. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients. Oncotarget. 2017;8(46):81343–9.

Article  PubMed  PubMed Central  Google Scholar 

O’Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur J Cancer. 2021;152:223–32.

Article  CAS  PubMed  Google Scholar 

Abad-Sazatornil MR, Arenaza A, Bayo J, Garcia Mata J, Guinea De Castro JM, Leon J, et al. Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study. BMC Health Serv Res. 2021;21(1):320.

Article  PubMed  PubMed Central  Google Scholar 

Altini M, Gentili N, Balzi W, Musuraca G, Maltoni R, Masini C, et al. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):503–9.

Article  PubMed  Google Scholar 

Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs. 2018;29(8):791–801.

Article  CAS  PubMed  Google Scholar 

Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227–33.

PubMed  PubMed Central  Google Scholar 

Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ. Assessing the transition from intravenous to subcutaneous delivery of rituximab: benefits for payers, health care professionals, and patients with lymphoma. PLoS ONE. 2022;17(1): e0261336.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stewart D, Aucoin JS, Crosbie T, Forman M, Lye E, Christofides A, Mitha A. Update on the subcutaneous administration of rituximab in Canadian cancer centres. Curr Oncol. 2020;27(2):113–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Munoz R, Quero C, Perez-Persona E, Domingo-Garcia A, Perez-Lopez C, Villaescusa-de-la-Rosa T, et al. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. 2020;188(5):661–73.

Article  CAS  PubMed